



CURRENT PROSPECTIVE IN THE MANAGEMENT OF DEPRESSION USING OFF LABELLED DRUGS AND ADVANCED DRUGS

VIVEK ARADHYA M V¹ AND JYOTHI Y^{2*}

- 1:** Student, Department of Pharmacology, Krupanidhi College of Pharmacy, Bengaluru-560035,
Karnataka
- 2:** Associate Professor, Department of Pharmacology, Krupanidhi College of Pharmacy, Bengaluru-
560035, Karnataka

***Corresponding Author: Dr. Jyothi Y: E Mail: jokiran05@gmail.com**

Received 10th July 2022; Revised 15th Sept 2022; Accepted 19th Oct. 2022; Available online 1st July 2023

<https://doi.org/10.31032/IJBPAS/2023/12.7.7245>

ABSTRACT

Depression is an affective condition that puts people's health at risk, with considerable and chronic depression as its principal clinical hallmark. Depression is a serious health issue that primary care physicians frequently encounter. Primary care clinicians have a crucial role in the treatment of depression and its associated medical comorbidities, but they experience difficulties in detecting and treating the disorder. We present a method for diagnosing depression that considers current evidence-based criteria and puts them into practise. Prescriptions for antidepressants are steadily increasing. The fact that they may be used off-label is one of the causes behind this development. Non-indicated usage, which incorporates different doses or durations than what is recommended, as well as medicine repurposing, accounts for up to one-third of all prescriptions. The five kinds of antidepressants are discussed, as well as their methods of action and major adverse effects. The most prevalent antidepressant off-label applications are covered. When antidepressants are used to treat different disorders, depression is frequent comorbidity, although effective therapeutic results have been reported even when depression isn't really present. Finally two different antidepressants are developed and they approved from FDA and it was released into the market immediately those are esketamine nasal spray and brexanolone I.V Injection are discussed below.

Keywords: Formalized assessment and intensity evaluation, electroencephalography, off-labelled drugs, esketamine, brexanolone

INTRODUCTION

Depression is a serious health issue that primary care physicians frequently encounter. In the United States, over eight million doctors' visits for depression are made each year, with a majority of them occurring in prime care [1]. Likewise, within the United Kingdom, over 3rd of every visit's with a public practitioner are calculable to encompass a mental state components, Ninety percent of patients are being treated and look after their mental condition alone in an exceedingly prime care settings [2]. Depression is a wide term that encompasses a variety of mental illnesses [3]. The depression disorder is the world's third leading source of disease burden [4]. Depression is a mood illness that occurs on a regular basis. Low mood, slurred speech and movement, mental impairment, and loss of interest are some of the clinical signs. In the workplace, self-guilt, self-awareness of insignificance, and Suicidal ideation is one of the most prevalent symptoms, it is harmful to everyone [5]. Depression may be passed down across generations [6]. When it happens, it usually happens between the ages of 15 and 30. Women are substantially more likely than males to have a family history of depression. Depression is more common and lasts longer in different countries and locations. However, the great global frequency and durability of severe depression confirms the disorder's growing global significance [7]. In accordance with the WHO, depression has become a

global problem, affecting between 300 to 450 million people worldwide, ranging from toddlers to adults and the elderly [8].

The 12-month prevalence of depression illness varies a lot by country, but it's around 6% worldwide [9]. Depression has a threefold lifetime risk (15–18%), indicating that severe depressive illness is frequent, with about one in every five persons experiencing an episode at some point in their lives [10]. As a result, one out of every 10 patients in primary care has depressed symptoms. In particular, when comparing high-income countries (5.5%), low-income and middle-income countries (5.9%), the 12-month prevalence of major depressive illness is strikingly similar [11-12]. Depression is linked to a number of elements, including genetics, environment, biology, culture, and psychology. Depression could strike at regardless of ages, but it's the most common in the 2nd and 3rd decades of existence [9, 13-14]. The prevalence estimates differ depending on the age group, culminating a mature adult, with a generality of 7.5 percent for females and 5.5 percent for males aged fifty five to seventy four years [15]. By 2030, it will have risen to the first place [16]. Traditionally, depression is diagnosed by a diagnostic interview or psychological probing depending on the intensity of symptoms. Questioning-based assessment, on the other hand, has a number of flaws, including medical experience and

personal involvement [17]. Depression is a difficult diagnosis to make because it has so many symptoms and can have a negative impact on one's health. As a result, individuals require a Psychologist with extensive experience in the treatment of depression. For all of the reasons stated above, we created an expert system to assist psychologists in identifying depression and prescribing the proper medication. An expert Systems are computer application of Artificial Intelligence (AI) that comprises a knowledge base and an inference engine [18].

TYPES OF DEPRESSION

We've discovered various different types of depression in recent years, and they're as follows:

Major depression:

The global burden of disease is largely driven by the prevalence of major depressive disorder (MDD). In fact, it is the major source of impairment as judged by the number of years lived with disability (YLDs) and is currently ranked second in disability adjusted life years (DALYs). Chronic antidepressants (ADs), which have the main effect of increasing monoaminergic neurotransmission, are usually used to treat MDD primarily initially additionally, Serotonergic and noradrenergic transporters are blocked by selective serotonin reuptake inhibitors or tricyclic ADs, respectively, or monoamine oxidase inhibitors block their degradation [19-20].

Bipolar disorder:

The bipolar affective disorder (bipolar) is a multi-factorial illness distinguished by mood problems, neuropsychological challenges, immune and physiological changes, and functional problems. Globally, it accounts for one of the most common reasons of incapacity, and its associated rates of premature mortality relate both to medical comorbidity and suicide [21].

Prenatal depression:

It's common for pregnant women to suffer from depression, anxiety, and psychological distress because of the physiological, hormonal, and psychological changes caused by pregnancy. When it comes to unfavourable maternity results and the growth of kids, a females poor psychological wellbeing during maternity can affect the mother and her child profoundly. Women suffering from depression during the perinatal period are most common world-wide. It is estimated that about 15% of women will experience depression during their lifetime, with the likelihood of being highest during pregnancy and after childbirth [22].

Postpartum depression:

Postpartum depression is a significant mental illness that affects women after they give birth. The majority prevalent obstacle after childbirth, postpartum depression, has a detrimental influence on the mother, with around 20% of postpartum deaths being caused by suicide [23].

Seasonal affective disorder (SAD):

SAD or unhappy is outlined within the Diagnostic and applied math Manual of Mental Disorders, Fifth Edition (DSM-5) as a kind of repeated major major affective disorders with a rhythm of the seasons. This sort of sadness only happens at certain times of the year. A seasonal pattern is thought to be present in ten percent to twenty percent of recurrent depression episodes [24-25].

ETIOLOGY

Depression can be triggered by a variety of factors as follows.

Abuse:

As you become aged, physical, sexual, and mental abuse might increase susceptibility to depression [26].

Age:

Depressive disorders are much more common among the elderly. Other factors, such as living alone and lack OF social support, might aggravate the problem [27].

Certain medications:

Certain drugs, for example; Isotretinonin (used to treat acne) [28], Interferon- α (An anti viral drug) [29] and Corticosteroids, Can increase your risk of depression [30].

Death or a loss:

Sadness or grief caused by the death or loss of a loved one may raise the risk of depression [31].

Gender:

Females are almost twice as likely as men to suffer from depression. Nobody is sure why. Hormonal fluctuations that women experience

at different phases of their lives may be an influence [32].

Genes:

There may be a familial history of depression. Depression risk is thought to be a complex characteristic, suggesting that there are likely many different genes, each having a tiny effect, rather than a single gene that influences illness risk [33]. The genetics of depression, like those of other mental disorders, are more intricate than those of simply inherited illnesses such as Huntington's chorea or cystic fibrosis [34].

Other personal problems:

Clinical depression can be triggered by social isolation as a result of different mental illnesses via being abandoned by a family or social community [35].

Medical students:

Medical students are exposed to a multitude of elements during their academic and clinical studies that have been shown to lead to high degrees of sadness and stress [36].

Cancer:

In individuals with common malignancies, major depression is linked to a worse chance of survival and also linked with hair loss and pain of chemotherapy [37].

Alopecia:

Depression is linked to difficulties in social life and inter personal connection, stress induced by hair loss and dissatisfaction among males with androgenic alopecia [38].

Covid 19 in COPD patients:

Some COPD patients will be more subject to mental disease symptoms and disorders such as post-traumatic stress illness, fear, anxiousness, and despair as well as suicidal thoughts. Even in normal circumstances about 40% of COPD patients have clinically significant depression symptoms (ex: excessive weariness, drop of desire in pleasure events) and thirty-six percent experience anxiety symptoms (ex: uneasiness, fear, and panic) that may require medical attention. Anxiety and despair are caused by a variety of factors in COPD patients. Causes of higher depression symptoms in COVID-19 pandemic patients with chronic respiratory problems [39].

DIAGNOSIS

Two order frameworks are broadly utilized: the fifth version of Diagnostic and Statistical Manual of Mental Disorders (DSM-5), created by the Association of American Psychiatric, and the Worldwide International Classification of Diseases and Related Health Problems, eleventh edition (ICD-11), created and as of late refreshed by WHO. There hasn't been a study that compares the Diagnostic and Statistical Manual of Mental Disorders-5 and International Classification of Diseases and Related Health Problems-11 in terms of identifying depression. Nevertheless, there has been substantial discussion over the cohabitation of DSM-IV and ICD-10 in general [40-41] and a single study looked at the differences between the two approaches in terms of identifying depression. The intensity

of depression, which is a mental illness, differed little between the Diagnostic and Statistical Manual of Mental Disorders-IV and International Classification of Diseases and Related Health Problems-10 criteria for diagnosis, according to a 2010 study in Japan that used item response theory to analyze the Diagnostic and Statistical Manual of Mental Disorders-IV and International Classification of Diseases and Related Health Problems-10 criteria for depressive disorders in three-fifty-three patients. The milder end of the depression spectrum was found to be more susceptible to ICD-10 than DSM-IV. Yet there have been some inequalities in intensity among those who responded; the larger part of these identified with a serious or modest depressive event based on International Classification of Diseases-10 criteria were diagnosed as well with major depression events based on Diagnostic and Statistical Manual of Mental Disorders-IV criteria. Diagnostic and Statistical Manual of Mental Disorders-5 distinguishes between a set of 8 Depression states, which includes Disturbing Mood Dysruptive Disorder, MDD, Prolonged Depressive Disorder (Dysthymia), Premenstrual Dysphoric Disorder, Substance Use/Drugs, Depressive Disorder Due to Another Medical Condition, Other Specified Depressive Disorder, and unspecified depressive disorder. Also, the International Classification of Diseases-11 order of burdensome problems incorporates an event

burdensome jumble, intermittent burdensome problem, dysthymic jumble, blended burdensome and uneasiness issue, premenstrual dysphoric turmoil, other determined burdensome problem, what's more undefined burdensome issue. The existence of a unhappy or blank mood followed by bodily and analytical alterations especially limit a individual's capacity to the activity is a usual characteristic divided into many depressive disorders over all categorization techniques, but they differ in length, timing, and origin [41].

Formalized assessment and intensity evaluation:

A proper findings of a significant burdensome issue utilizing the DSM-5 measures expects something like a crucial signal (less temperament, a drop in enthusiasm and delight, wastage of power) to be available, though the International classification of diseases-11 standards needs discouraged temperament and decreased curiosity in exercises to analyze a burdensome segment. In each, manifestations ought to be available for somewhere around fourteen days and every indication ought to be present at adequate seriousness for the greater part of each day. For a diagnosis of depression, the Diagnostic and Statistical Manual of Mental Disorder-5 requires at least 5 in 9 symptoms, although the newer Interational classification of disease-11 categorization system does not specify the no. of indications required. Rather than relying

just on symptom count, the intensity of individual's depression ought to be determined by degree of impairment in terms of functionality, which includes intensity of symptoms. Although this method makes severity rating a little more biased, emphasising the distinction is crucial because therapy that is supported by facts is directed by the intensity. The number, kind, and severity of symptoms present, as well as the degree of functional impairment, are used to categorise depressive events as mild, moderate and severe in both systems [41].

Alternate psychiatric diagnoses:

Other depressive illnesses may cause depressed symptoms that do not match DSM-5 criteria for severe depression or ICD-11 criteria for a single episode or recurring depressive disorder. The arrangement measures ought to be counselled straightforwardly for a full portrayal of every burdensome confusion to help the essential consideration supplier in making a differentiation and, subsequently, a precise conclusion [41].

Bipolar disorder:

Any tolerant who gives indications of depression ought to likewise be assessed for conceivable bipolar issue. Individuals with bipolar turmoil are regularly diagnosed incorrectly as having a significant burdensome problem, especially at introductory show in the essential consideration setting, as a few investigations have observed that in excess of

33% of these patients remain diagnosed incorrectly for as long as decades. Bipolar illness probably happens in 3.4-9.0% of essential consideration patients with sadness, openness to injury, restoratively unexplained side effects, or a mental protest. Strangely, by correlation, 20.9 to 30.8 percent of tolereents had +ve brings about investigations i.e pre-owned experimentation, However, misdiagnosing bipolar illness as MDD might show the use of anti-depressants as an alternative of mood stabilisers, which can result in mania and freequent cycling [41].

Alternate physical diagnoses:

Medical illnesses that resemble depression should also be ruled out at the outset. This can be difficult because there is no single test, examination, or technique that can quickly and efficiently identify the aetiology of the presenting symptomatology. Four directing inquiries have been proposed to help with laying out a circumstances and logical results connection between mental manifestations and actual discoveries:

Is the mental symptom's appearance unusual?

Is there a temporal link between the medical condition or substance usage and the psychological symptom?

Is a main mental condition more likely to explain the psychiatric symptoms?

Is the psychological disorder a direct result of a physical condition or substance abuse? [41-43]

Depression and suicide risk:

Individuals should be checked for suicidal behavior by primary care doctors once they have been diagnosed with depression. Despondency is a significant gamble thing that impacts each endeavored and finished suicide, eighty and past filled with self mischief endeavors, in mix with a background marked by very much evolved self destruction plan, put the individual at a highly noteworthy inevitable gamble of finishing a self destruction endeavour. Primary care physicians have an important role in suicide prevention because nearly 50 percent of individuals who commit suicide had contact with them in the month leading up to their death. A systematic analysis of 21 research published in 2017 looked at the likelihood of bias and diagnostic accuracy when it came to suicide and suicidal attempts. Meta investigation of 5 instrument across the examinations showed that none of the instruments came to the foreordained benchmark (eighty percent responsiveness and half explicitness) for the self destruction result or self destruction endeavour result. With few special cases, low figures were noticed for the positive prescient incentive for the self destruction result (1-13%) [41].

Using electroencephalography (EEG) recordings:

The non-stationary and non-linear functioning of brain-signals is depicted by electroencephalography (EEG) recordings. The electroencephelography is a low-cost

instrument that may be used to decipher complicated brain activity. There hasn't been much progress made on automated identification of depression using electroencephalography signals, which might be owing to a lack of community databases. There have been a few efforts to identify a link between EEG records and depression. When a depressed patient's electroencephalography from frontal and temporal areas is compared to that of a healthy person, several abnormalities emerge. In comparison to a healthy participant, depressed patients exhibit

decreased left-sided frontal activation and higher activity in band. It's worth noting that a rise in alpha band energy suggests a drop in activation. Similarly, as compared to non-depressed individuals, depressed patients had more activation (lower alpha band energy) on right sided frontal electroencephelography signals. In depressive individuals, there is also a lower complexity (greater predictability) of brain activity as compared to normal participants, indicating less engagement with the environment [44].

Table 1: Electroencephalography readings

Category of subject	No. of subjects	Data sets	Frequency of sample	No. of sample
Depressive patients	15	4200	256Hz	2000
Normal	15	4200	256Hz	2000




Figure 1: Normal and depressed electroencephalograph signals [44]

CURRENT DRUG TREATMENTS FOR DEPRESSION [45]

Table 2: Current drug treatments

Class	Drugs	Mechanism of action	Side effects
Selective serotonin reuptake inhibitors(SSRI)	Citalopram Fluoxetine Escitalopram Vortioxetine	Reuptake inhibitors(Serotonin transporter) Reuptake inhibitor (Serotonin transporter), Receptor partial agonist(5-Hydroxy tryptamine-1A)	Weight gain, insomnia, nervousness, tremors, nausea sexual dysfunction, fatigue, anxiety, drowsiness, blurred vision, diarrhea, dizziness, dry mouth.
Serotonin and Nor epinephrine uptake inhibitors	Desvenlafaxine Venlafaxine Milnacipran	Reuptake inhibitors (Serotonin transporter and Norepinephrine transporter)	Excessive sweating, nausea, loss of appetite, dizziness, headache, dry mouth.
Tricyclic anti	Trimepramine	Receptor antagonist(5-Hydroxy	Nausea, blurred vision, constipation,

depressant	Desipramine Protryptiline Nortryptiline Imipramine	tryptamine-2 and D2). Reuptake inhibitor(Norepinephrine transporter). Reuptake inhibitors (Serotonin transporter and Norepinephrine transporter).	dry mouth, drop in blood pressure when moving from sitting to standing, urine retention, drowsiness, tremor, weight loss,
Monoamine oxidase inhibitors	Isocarboxazid Phenelzic Clobemix Selgeline	Enzyme inhibitor (Monoamine oxidase-A and -B) Reversible enzyme inhibitor (Monoamine oxidase-B and -A)	Dry mouth, nausea, diarrhea, constipation, headache, insomnia, drowsiness, dizziness, involuntary muscle jerks, low blood pressure.
Atypical antidepressant	Bupropion Nefazodone	Reuptake inhibitor, (Norepinephrine transporter, dopamine transporter), releaser (NE, DA) Receptor antagonist(5-HT-2)	Agitation, headache, insomnia, loss of appetite, weight loss, sweating Diarrhea, nausea, dizziness, constipation, insomnia, drowsiness.

FDA APPROVED OFF-LABELLED DRUGS

Table 3: Off-labelled drugs

NAME OF THE DRUGS	OFF-LABELLED USE OF DRUGS	MECHANISM OF ACTION OF DRUGS
Duloxetine	Chronic pain of fibromyalgia	Increases the dopamine levels as a result it causes selective serotonin and norepinephrine and nor-adrenaline reuptake inhibitor ^[45-46] .
Milnacipran	Chronic pain of fibromyalgia	Increases the dopamine levels as a result it causes selective serotonin and norepinephrine and nor-adrenaline reuptake inhibitor ^[47] .
Bupropion	Cessation of smoking	Norepinephrine and dopamine reuptake are slightly inhibited. Dopamine reuptake inhibition is said to be quite strong, whereas norepinephrine uptake is said to be less so ^[48] .
Venlafaxine	Complex pain syndrome, migraine, diabetic neuropathy, fibromyalgia	Increases norepinephrine, serotonin and dopamine by inhibiting transport of proteins and preventing their reuptake at the presynaptic terminal. Serotonin reuptake inhibition is more powerful than norepinephrine reuptake ^[49] .
Paroxetine	Hot flashes, night sweat which are associated with menopause, dysphoric premenstrual disorder	It inhibits the serotonin reuptake transporter (SERT) and hence enhance synaptic serotonin levels ^[50] .

NEWER DRUGS UNDER CLINICAL TRIALS [51]

Table 4: Drugs under clinical trials

DRUG NAME	SPONSOR/CLINICAL TRIAL.GOV IDENTIFIER NUMBER	ENROLMENT	STATUS
Omega-3 fatty acids	L. Eugene Arnold collaborated with national institute of mental health NCT01341925	Actual enrolment:- 73 participants	Phase-1 clinical trial
Amlodipine	Gated health NHS Foundation Trust NCT01557153	Actual enrolment:-80 participants	Phase 3 clinical trial
Escitalopram	University of Cincinnati NCT04245748	Actual recruitment:- 84 participants	Phase-4 clinical trial
Botulinum toxin type A neurotoxin complex	Seton healthcare family NCT01392963	Actual recruitment:- 30 participants	Phase-2 clinical trial
ER beta agonist (lilly compound LY500307)	National institute of mental health NCT03689543	Estimated enrolment:- 54 participants	Phase-2 clinical trial

APPROVED DRUGS FOR DEPRESSION

Esketamine nasal spray: Immediate release on 05/03/2019

The USFDA recently accepted Spravato (esketamine) nasal spray for the treatment of depression in individuals who have tried but failed to benefit via existing antidepressant medications (therapy-opposing depression). Due to the gamble of genuine unfriendly results coming about because of sedation and separation brought about by Spravato organization, and the potential for misuse and abuse of the medication, it is just accessible through a limited appropriation framework, under a REMS (Risk Evaluation and Mitigation Strategy). Individuals with MDD who have failed to respond to treatment despite at least two attempts at appropriate doses of antidepressants for an appropriate duration in the current episode are considered treatment-resistant depression. The s-enantiomer of ketamine is escetamine. Ketamine is made up of two enantiomers: one is positive and the other is negative (mirror image molecules).

Side effects: The most prevalent adverse effects seen by individuals treated with Spravato in clinical studies were disassociation, dizziness, nausea, sleepiness, vertigo, reduced sensation or sensitivity (hypoesthesia), anxiety, lethargy, raised blood pressure, vomiting, and feeling drunk [52].

Brexanolone I.V Injection: Immediate release on 19th March 2019

The United States FDA has authorized Zulresso (brexanolone) injection for intravenous (IV) use in adult women suffering from postpartum depression (PPD). This is the FDA's first medicine authorized for postpartum depression. This approval marks the primary time a drug has been specifically approved to treat postnatal depression, providing a very important new treatment option, aforementioned artist Farchione, M.D., acting director of the Division of psychological medicine merchandise within the FDA's Center for Drug Analysis and Research.

Side effects: In clinical tests, drowsiness, dry mouth, unconsciousness, and flushing were among the most common adverse effects reported by those using Zulresso. Medical providers should consider altering a patient's medication plan, including stopping Zulresso, if their postpartum depression worsens or they exhibit sudden suicidal thoughts and acts [53].

CONCLUSION

Antidepressant usage has increased dramatically in the countries in recent years. As primary care physicians respond to their patients increasing health requirements and psychological complexity, they encounter several hurdles. They're becoming more common in depression screening, assessment, and therapy. As a result, primary care physicians should cure depression like any other chronic condition. Antidepressants do not have a high likelihood of becoming addicted. A bigger issue is therapeutic

cessation owing to a lack of immediate effects. With the introduction of esketamine, a quick antidepressant derived from the hallucinogenic ketamine, this scenario is beginning to change along with this brexanolone is also approved by FDA which is given for the treatment of postnatal depression. The approval of innovative medications and the large number of clinical trials involving this class of therapy indicate that they will continue to play an important role in medicine for many years.

REFERENCE

- [1] Ferenchick EK, Ramanuj P, Pincus HA. Depression in primary care: part 1-screening and diagnosis. *BMJ*. 2019 Apr 8;365.
- [2] Central London NHS. (Westminster) CCG. Commissioning for Value: Mental health and dementia pack. 2017.
<https://www.england.nhs.uk/wp-content/uploads/2017/07/cfv-central-london-westminster-mhidp.pdf>.
- [3] Ridley M, Rao G, Schilbach F, Patel V. Poverty, depression, and anxiety: Causal evidence and mechanisms. *Science*. 2020 Dec 11;370(6522):eaay0214.
- [4] Cademartori MG, Gastal MT, Nascimento GG, Demarco FF, Corrêa MB. Is depression associated with oral health outcomes in adults and elders? A systematic review and meta-analysis. *Clinical oral investigations*. 2018 Nov;22(8):2685-702.
- [5] Chen L. Advances in research on the pathogenesis of depression based on signaling pathways. In *E3S Web of Conferences 2020* (Vol. 218, p. 03017). EDP Sciences.
- [6] Sawyer KM, Zunszain PA, Dazzan P, Pariante CM. Intergenerational transmission of depression: clinical observations and molecular mechanisms. *Molecular psychiatry*. 2019 Aug;24(8):1157-77.
- [7] Häfner H. From onset and prodromal stage to a life-long course of schizophrenia and its symptom dimensions: How sex, age, and other risk factors influence incidence and course of illness. *Psychiatry journal*. 2019 Apr 16;2019.
- [8] Zhou S, Gao L, Liu F, Tian W, Jin Y, Zheng ZJ. Socioeconomic status and depressive symptoms in older people with the mediation role of social support: A population-based longitudinal study. *International journal of methods in psychiatric research*. 2021 Dec;30(4):e1894.
- [9] Kessler RC, Bromet EJ. The epidemiology of depression across cultures. *Annual review of public health*. 2013 Mar 18;34:119-38.
- [10] Bromet E, Andrade LH, Hwang I, Sampson NA, Alonso J, De Girolamo

- G, De Graaf R, Demyttenaere K, Hu C, Iwata N, Karam AN. Cross-national epidemiology of DSM-IV major depressive episode. *BMC medicine*. 2011 Dec;9(1):1-6.
- [11] Vos T, Barber RM, Bell B, Bertozzi-Villa A, Biryukov S, Bolliger I, Charlson F, Davis A, Degenhardt L, Dicker D, Duan L. Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. *The lancet*. 2015 Aug 22;386(9995):743-800.
- [12] Vos T, Flaxman AD, Naghavi M, Lozano R, Michaud C, Ezzati M, Shibuya K, Salomon JA, Abdalla S, Aboyans V, Abraham J. Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010. *The lancet*. 2012 Dec 15;380(9859):2163-96.
- [13] Moffitt TE, Caspi A, Taylor A, Kokaua J, Milne BJ, Polanczyk G, Poulton R. How common are common mental disorders? Evidence that lifetime prevalence rates are doubled by prospective versus retrospective ascertainment. *Psychological medicine*. 2010 Jun;40(6):899-909.
- [14] Hirschfeld RM. The epidemiology of depression and the evolution of treatment. *The Primary Care Companion for CNS Disorders*. 2012 Jul 15;14(Suppl 1: Editor Choice):26328.
- [15] McCoy KT, Costa CB, Pancione K, Hammonds LS. Anticipating changes for depression management in primary care. *Nursing Clinics*. 2019 Dec 1;54(4):457-71.
- [16] Bachmann M, Päske L, Kalev K, Aarma K, Lehtmets A, Ööpik P, Lass J, Hinrikus H. Methods for classifying depression in single channel EEG using linear and nonlinear signal analysis. *Computer methods and programs in biomedicine*. 2018 Mar 1;155:11-7.
- [17] Sharma M, Achuth PV, Deb D, Puthankattil SD, Acharya UR. An automated diagnosis of depression using three-channel bandwidth-duration localized wavelet filter bank with EEG signals. *Cognitive Systems Research*. 2018 Dec 1;52:508-20.
- [18] Alshawwa IA, Elkahlout M, El-Mashharawi HQ, Abu-Naser SS. An Expert System for Depression Diagnosis.
- [19] Kraus C, Kadriu B, Lanzenberger R, Zarate Jr CA, Kasper S. Prognosis

- and improved outcomes in major depression: a review. *Translational psychiatry*. 2019 Apr 3;9(1):1-7.
- [20] Planchez B, Surget A, Belzung C. Animal models of major depression: drawbacks and challenges. *Journal of Neural Transmission*. 2019 Nov;126(11):1383-408.
- [21] Ropper AH. Andre F. Carvalho, MD, Ph. D., Joseph Firth, Ph. D., and Eduard Vieta, MD, Ph. D. *N Engl J Med*. 2020;383:58-66.
- [22] Sheeba B, Nath A, Metgud CS, Krishna M, Venkatesh S, Vindhya J, Murthy GV. Prenatal depression and its associated risk factors among pregnant women in Bangalore: a hospital based prevalence study. *Frontiers in public health*. 2019 May 3;7:108.
- [23] Payne JL, Maguire J. Pathophysiological mechanisms implicated in postpartum depression. *Frontiers in neuroendocrinology*. 2019 Jan 1;52:165-80.
- [24] Drew EM, Hanson BL, Huo K. Seasonal affective disorder and engagement in physical activities among adults in Alaska. *International journal of circumpolar health*. 2021 Jan 1;80(1):1906058.
- [25] American Psychiatric Association, Diagnostic and statistical manual of mental disorders. Fifth ed (DSM-5). Washington, DC: American Psychiatric Association; 2013.
- [26] Targum SD, Nemeroff CB. The effect of early life stress on adult psychiatric disorders. *Innovations in clinical neuroscience*. 2019 Jan 1;16(1-2):35.
- [27] Domènech-Abella J, Mundó J, Haro JM, Rubio-Valera M. Anxiety, depression, loneliness and social network in the elderly: Longitudinal associations from The Irish Longitudinal Study on Ageing (TILDA). *Journal of affective disorders*. 2019 Mar 1;246:82-8.
- [28] Suuberg A. Psychiatric and developmental effects of isotretinoin (retinoid) treatment for acne vulgaris. *Current Therapeutic Research*. 2019 Jan 1;90:27-31.
- [29] Mesripour A, Fashi YA, Hajhashemi V. The effect of soybean diet on interferon alpha induced depression in mice. In *Proceedings for Annual Meeting of The Japanese Pharmacological Society WCP2018 (The 18th World Congress of Basic and Clinical Pharmacology) 2018* (pp. PO3-1). Japanese Pharmacological Society.
- [30] García CC, Sánchez EA, Huerta DH, Gómez-Arnau J. Covid-19 treatment-induced neuropsychiatric adverse effects. *General Hospital Psychiatry*. 2020 Nov;67:163.

- [31] Meichsner F, O'Connor M, Skritskaya N, Shear MK. Grief before and after bereavement in the elderly: an approach to care. *The American Journal of Geriatric Psychiatry*. 2020 May 1;28(5):560-9.
- [32] Audet MC. Stress-induced disturbances along the gut microbiota-immune-brain axis and implications for mental health: does sex matter?. *Frontiers in neuroendocrinology*. 2019 Jul 1;54:100772.
- [33] Thejavathi UC. Depression in Chronic Kidney Disease Patients. *International Journal of Research in Engineering, Science and Management*. 2021 Mar 11;4(3):12-6.
- [34] Thejavathi UC. Depression in Chronic Kidney Disease Patients. *International Journal of Research in Engineering, Science and Management*. 2021 Mar 11;4(3):12-6.
- [35] Matthews T, Qualter P, Bryan BT, Caspi A, Danese A, Moffitt TE, Odgers CL, Strange L, Arseneault L. The developmental course of loneliness in adolescence: Implications for mental health, educational attainment, and psychosocial functioning. *Development and psychopathology*. 2021 Nov 21:1-0.
- [36] Moir F, Yields J, Sanson J, Chen Y. Depression in medical students: current insights. *Advances in medical education and practice*. 2018;9:323.
- [37] Calderon C, Carmona-Bayonas A, Hernández R, Ghanem I, Castelo B, de Castro EM, Ferreira E, Ciria L, Muñiz M, Jimenez-Fonseca P. Effects of pessimism, depression, fatigue, and pain on functional health-related quality of life in patients with resected non-advanced breast cancer. *The Breast*. 2019 Apr 1;44:108-12.
- [38] Jung-Won KI. Factors Influencing Depression in Korean Men with Androgenic Alopecia. *Iranian Journal of Public Health*. 2021 Mar;50(3):624.
- [39] Yohannes AM. COPD patients in a COVID-19 society: depression and anxiety. *Expert Review of Respiratory Medicine*. 2021 Jan 2;15(1):5-7.
- [40] Regier DA, Kuhl EA, Kupfer DJ. The DSM-5: Classification and criteria changes. *World psychiatry*. 2013 Jun;12(2):92-8.
- [41] Ferenchick EK, Ramanuj P, Pincus HA. Depression in primary care: part 1—screening and diagnosis. *BMJ*. 2019 Apr 8;365.
- [42] Freudenreich O. Differential diagnosis of psychotic symptoms:

- medical mimics. *Psychiatr Times*. 2010 Dec 1;27(12):56-61.
- [43] McKee J, Brahm N. Medical mimics: Differential diagnostic considerations for psychiatric symptoms. *Mental Health Clinician*. 2016 Nov;6(6):289-96.
- [44] Sharma M, Achuth PV, Deb D, Puthankattil SD, Acharya UR. An automated diagnosis of depression using three-channel bandwidth-duration localized wavelet filter bank with EEG signals. *Cognitive Systems Research*. 2018 Dec 1;52:508-20.
- [45] Skånland SS, Cieślak-Pobuda A. Off-label uses of drugs for depression. *European journal of pharmacology*. 2019 Dec 15;865:172732.
- [46] Dhaliwal JS, Spurling BC, Molla M. Duloxetine.
- [47] Gupta H, Girma B, Jenkins JS, Kaufman SE, Lee CA, Kaye AD. Milnacipran for the Treatment of Fibromyalgia. *Health Psychology Research*. 2021;9(1).
- [48] Huecker MR, Smiley A, Saadabadi A. Bupropion. *StatPearls [Internet]*. 2021 Aug 26.
- [49] Singh D, Saadabadi A. Venlafaxine. *StatPearls [Internet]*. 2021 Aug 6.
- [50] Kowalska M, Nowaczyk J, Fijałkowski Ł, Nowaczyk A. Paroxetine—Overview of the molecular mechanisms of action. *International Journal of Molecular Sciences*. 2021 Jan;22(4):1662.
- [51] <https://clinicaltrials.gov/ct2/results?cond=depression&term=&cntry=&state=&city=&dist=>
- [52] <https://www.fda.gov/news-events/press-announcements/fda-approves-new-nasal-spray-medication-treatment-resistant-depression-available-only-certified>.
- [53] <https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-post-partum-depression>